Summary

Eligibility
for people ages 2-17 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Philip Rosenthal

Description

Summary

The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.

Official Title

A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection

Keywords

Chronic Hepatitis B, CHB, HBV, Hepatitis A, Hepatitis B, Virus Diseases, Herpesviridae Infections, Hepatitis, Chronic Hepatitis, TAF, Open-Label TAF

Eligibility

You can join if…

Open to people ages 2-17

  • Males and non-pregnant, non-lactating females
  • Weight at screening as follows:
    • Cohort 1 = ≥ 35 kg (≥ 77 lbs)
    • Cohort 2 Group 1 = ≥ 25 kg (≥ 55 lbs)
    • Cohort 2 Group 2 = ≥ 14 kg to < 25 kg (≥ 30 lbs to <55 lbs)
    • Cohort 2 Group 3 = ≥ 10 kg to < 14 kg (≥ 22 lbs to < 30 lbs) or
      • 14 kg to < 25 kg (≥ 30 lbs to < 55 lbs)
  • Willing and able to provide written informed consent/assent (child and parent/legal guardian)
  • Documented evidence of CHB (eg, HBsAg-positive for ≥ 6 months)
  • HBeAg-positive, or HBeAg-negative, chronic HBV infection with all of the following:
    • Screening HBV DNA ≥ 2 × 104 IU/mL
    • Screening serum ALT > 45 U/L (> 1.5 × ULN: 30 U/L) and ≤ 10 × ULN (by central laboratory range)
  • Treatment-naive or treatment-experienced will be eligible for enrollment.
  • Estimated creatinine clearance (CLCr) ≥ 80 mL/min/1.73m2 (using the Schwartz formula)
  • Normal ECG

You CAN'T join if...

  • Females who are pregnant or breastfeeding
  • Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study.
  • Coinfection with hepatitis C virus (HCV), HIV, or hepatitis D virus (HDV)
  • Evidence of hepatocellular carcinoma (Note: if screening alpha-fetoprotein (AFP) is < 50 ng/mL no imaging study is needed; however, if the screening AFP is > 50 ng/mL an imaging study is required)
  • Any history of, or current evidence of, clinical hepatic decompensation
  • Abnormal hematological and biochemical parameters
  • Chronic liver disease of non-HBV etiology (e.g., hemochromatosis, alpha-1 antitrypsin deficiency, cholangitis)
  • Received solid organ or bone marrow transplant
  • Currently receiving therapy with immunomodulators (eg, corticosteroids), or immunosuppressants
  • Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the Investigator
  • Malignancy within the 5 years prior to screening. Individuals under evaluation for possible malignancy are not eligible.
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance.

    Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

  • UCSF (UCSF) accepting new patients
    San Francisco California 94158 United States
  • Children's Hospital of Los Angeles accepting new patients
    Los Angeles California 90027 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Gilead Sciences
Links
Gilead Clinical Trials Website
ID
NCT02932150
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 150 study participants
Last Updated